The insulin-like growth factors (IGF-I 1 and IGF-II) bind with nanomolar affinities to specific binding proteins present in extracellular fluids (1) . These IGF-binding proteins (IGFBPs) prolong the half-life of the IGFs, are believed to participate in the in vivo folding of IGFs (2) , and inhibit IGF binding to the insulin receptor. The IGFBPs have also been shown to either inhibit or stimulate the growth-promoting effects the IGFs have on cell cultures, most likely by altering the interaction of IGFs with their cell surface receptors (3) .
There are at least six different IGFBPs that have homologous amino acid sequences. Human IGFBP-1, -2, -3, and -5 each contain 18 cysteine residues in conserved positions; IG-FBP-4 contains two additional cysteines; and IGFBP-6 has only 16. The characteristic N-terminal cysteine pattern of the IGFBPs, GC(G/S)CCXXCAXXXXXXC, can also be found e.g. in the human proteins MAC25 (4) and connective tissue growth factor. The disulfide mapping and three-dimensional structures of these binding proteins remain elusive.
Solution NMR structures of IGF-I (5-9) (Fig. 1) , IGF-II (10, 11) , and insulin itself (12, 13) are available. Several mutagenesis studies have addressed the localization of IGFBP binding determinants on the IGFs. A naturally occurring N-terminally truncated form of IGF-I, des (1) (2) (3) , has been found to be 5-10-fold more potent in stimulating protein synthesis in rat myoblasts (14) , explained by a 60-fold lower affinity for IGFBPs present in these cells (15) . Clemmons et al. (16) have found that mutation of the IGF-I residues 3 and 4 as well as 49 -51 leads to reduced affinity for IGFBP-1. A more detailed understanding of the nature of the interactions between the insulin-like growth factors and their moderating binding proteins may be used to aid design of more potent IGF-derived pharmaceutical agents.
In this article, we present a heteronuclear NMR study of 15 Nand 13 C-labeled IGF-I. By a comparison of the IGF-I chemical shifts in the presence and absence of IGFBP-1, a structural binding epitope could be defined. The NMR analysis indicates that three arginine side chains in IGF-I are affected by complex formation with IGFBP-1. To further confirm the identity and the importance of these interactions and to probe possible differences between the structural and functional binding epitope (17) , site-directed mutagenesis was utilized. Every IGF-I arginine was replaced by alanine through the construction of four single substituted variants, R21A, R50A, R55A, and R56A, and one double replacement mutant, R36A/R37A. The effect on binding was evaluated using Biosensor kinetic interaction analysis, and as a comparison, the binding of IGF-I to immobilized IGF-I receptor (IGF-I R ) in the presence of IG-FBP-1 was evaluated to test for the presence of overlapping residues involved in both IGFBP-1 and IGF-I R binding.
MATERIALS AND METHODS
Protein Production-The IGF-I variants were produced intracellularly in Escherichia coli as fusions to the IgG binding domain Z derived from the B domain of staphylococcal protein A (18) . The production of labeled IGF-I followed closely the previously published procedures for IGF-II labeling and IGF-I variant production (19, 20) . E. coli RV308 ompT containing the plasmid pKP522, was grown in defined minimal medium with ( 15 NH 4 ) 2 SO 4 as the sole source of nitrogen and, in the case of double labeling, ( 15 N and 13 C) with 13 C-glucose as the sole carbon source. Protein was recovered from inclusion bodies by resuspension in 6 M guanidine HCl followed by IgG affinity chromatography as described by Jansson et al. (20) . The IGF-I moiety was released from the Z fusion partner by hydroxylamine-mediated cleavage (20, 21) . Separation of the IGF-I products after cleavage was performed by cation exchange chromatography using a Mono S column (Amersham Pharmacia Biotech). The elution gradient was from 10 to 52% B in 20 min. Buffer A contained 20 mM ammonium acetate, pH 5.4, 10% ethanol; buffer B contained 1 M ammonium acetate, pH 5.4, 10% ethanol. The * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
final purification, separating native and mismatched IGF-I forms (22) , was performed using a C 8 reverse-phase HPLC column. IGFBP-1 and IGF-I R were produced in mammalian expression systems and purified as described (23) .
Sample Preparation-IGF-I labeled with 13 C and 15 N was studied by NMR either alone or in complex with IGFBP-1 at 600 M and pH 3.4. Between this pH and its pI value (4.8; determined by isoelectric focusing), IGFBP-1 precipitates. Previous observation of the aggregation tendencies of IGF-I, as well as IGFBP-1, when free in solution, dictated that the complex was formed at dilute concentrations with an excess of IGFBP-1, in 7 ml of 1 mM sodium citrate buffer and then subsequently concentrated by reduction of the sample volume to 200 l using a vacuum rotation concentrator.
Site-directed Mutagenesis-Introduction of point mutations in IGF-I was performed in a two-step sequential PCR reaction using two general IGF-I primers in combination with two specific primers for each mutation. The general primers were designed for the expression vector pKP522, containing a synthetic IGF-I gene (19) . The general 5Ј primer 5Ј-AGT AGA CGC GAA TTC TAA CGG -3Ј covered the EcoRI cloning site and the general 3Ј primer 5Ј-AAT CAG CAA GCT TCT AAG CAG ATT-3Ј covered the HindIII site. Mutations were introduced by first producing two separate PCR fragments from each general primer to a specific primer at the point of mutation. This results in two overlapping fragments, one from the 5Ј-end to the mutagenesis site and one from the mutagenesis site to the 3Ј-end. The obtained PCR fragments were mixed, and a second round of PCR using the general primers was performed. The mutation primers used for each variant were as follows: R21A:1, 5Ј-TTG TTT GCG GTG ACG CTG GTT T-3Ј; R21A:2, 5Ј-GTT AAA ATA AAA ACC AGC GTC A-3Ј; R3637A:1, 5Ј-GGT TCT TCT TCT GCT GCT GCT CC-3Ј R3637A:2, 5Ј-CCA GTC TGG GGA GCA GCA GCA G-3Ј; R50A:1, 5Ј-ATG CTG CTT TGC TTC ATG CG-3Ј; R50A:2, 5Ј-CGC AGG TCG CAT GAA GCA AAG-3Ј; R55A:1, 5Ј-TTC TTG CGA CCT GGC TCG TCT G-3Ј; R55A:2, 5Ј-ATA CAT TTC CAG ACG AGC CAG G-3Ј; R56A:1, 5Ј-CTT GCG ACC TGC GTG CTC TGA A-3Ј; R56A:2, 5Ј-CAA TAC ATT TCC AGA GCA CGC A-3Ј. The PCR reactions were performed according to Ref. 24 . PCR primers were synthesized by Cybergene AB (Huddinge, Sweden). PCR deoxynucleotides were obtained as a premixed 10 mM solution (Boehringer Mannheim) while the Taq polymerase was from Perkin-Elmer. All the mutations were verified using automated dideoxy sequencing on an ABI 373 (Applied Biosystems).
The IGF-I variant proteins were produced as described for labeled protein except for the use of Terrific Broth/Glycerol medium (Sigma). All purified proteins were verified by quantitative amino acid analysis, laser desorption mass spectrometry, and analytical reverse-phase HPLC. Circular Dichroism-CD spectra were recorded using a Jasco J 720 spectropolarimeter (Jasco, Japan). Protein samples were dissolved in 10 mM potassium phosphate buffer, pH 7.0, to a final concentration of 0.1 mg/ml. Spectra were recorded from 250 to 184 nm at a step resolution of 0.1 nm and a scanning speed of 5 nm/min. Each spectrum is the average of five accumulated scans. Subsequently, actual concentration of each protein sample was determined by quantitative amino acid composition analysis.
NMR Spectroscopy-All NMR experiments were performed on Varian Unity and Unity ϩ 500-and 600-MHz spectrometers. The following spectra were recorded: 1 H-15 N HSQC (25), 1 H-13 C CT-HSQC (26), HNCO (27) , HNCACB (28) , CBCA(CO)NH (29) , CBCA(CO)HA (30), three-dimensional HCC(CO)NH-total correlation spectroscopy, and three-dimensional CC(CO)NH-total correlation spectroscopy (31, 32) and simultaneous 15 N-and 13 C-edited three-dimensional nuclear Overhauser effect spectroscopy (33) .
The spectra were processed with the NMR-Pipe program (34) using linear prediction in the 15 N and/or 13 C dimensions of the three-dimensional spectra. The spectra were assigned with the interactive graphics program ANSIG (35) adapted for multidimensional heteronuclear NMR spectra (36) .
Biosensor Kinetic Measurements-The binding affinities of the IGF-I variants were measured using BIAcore real time kinetic interaction analysis (Biacore AB, Uppsala, Sweden). The measurements were performed as previously published (23), with IGFBP-1 or IGF-I R as the immobilized part of the complex. The acceptor protein was immobilized via primary amine groups utilizing NЈ-ethyl-NЈ-(dimethylaminopropyl)-carbodiimide/N-hydroxysuccinimide coupling reagents (37) . Protein absorption and coupling were performed at pH 4. Immobilization was performed at 5 l/min using 1ϫ HBS (10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.05% P20). All kinetic experiments were performed using 1ϫ HBS as the driving buffer at a flow rate of 8 l/min. The injection of analyte was controlled using the Kinject command in the BIAlogue control software. All of the variants were injected in concentrations of 20, 40, 80, 160, 320, and 640 nM for both the IGFBP-1 and IGF-I R experiments. Kinetic measurements were performed by injection of each analyte for 300 s followed by disassociation in buffer flow for 400 s. The temperature in all kinetic experiments was 25°C. Binding of IGF-I to IGF-I R in the presence of IGFBP-1 was tested using immobilized IGF-I R and free IGF-I in concentrations of 8, 16, 33, 66, and 131 nM and complexed to IGFBP in IGF-I/IGFBP-1 proportions of 2:1 and 1:5. Kinetic parameters were calculated using the kinetics evaluation software package BIAevaluation 2 (Biacore AB). Protein concentration was determined using quantitative amino acid analysis.
RESULTS
Earlier NMR studies of unlabeled IGF-I showed very poor spectral quality at pH values above 3.0 and in a concentration range of 3-7 mM due to dimerization (5) . Others have reduced the IGF-I self-association at 2-10 mM protein concentration, and thereby improved the spectral quality, by the addition of 10% (8) or 20% (9) acetic acid. In this study, we have not used acetic acid, since it influences the IGF-I/IGFBP-1 binding affinity. We found that spectral quality for IGF-I is marginally improved by dilution to submillimolar concentrations and confirm that, as pointed out by Cooke et al. (5) , elevated temperatures improve the spectral quality significantly.
We made use of IGF-I labeled with 15 N as well as 13 C and 15 N to aid these NMR studies. The molecular masses of the labeled IGF-I material were analyzed by electrospray mass spectrometry to determine the isotope incorporation levels. The mass of the 15 N-labeled IGF-I was found to be 7740, which corresponds to an 15 N incorporation level of 99.98%. The 13 C, 15 N-labeled IGF-I mass of 8063.5 corresponds to a 99.97% degree of isotope labeling.
The NMR signals from the backbone of 13 C, 15 N-IGF-I were initially assigned at 50°C and pH 3.4 for compatibility with previously published 1 H assignments (5) and optimization of the spectral quality. The NMR methodology used was to perform sequential walks in either HNCACB and CBCA(CO)NH (5) could assign 87% of the backbone and 72% out of the total number of protons. No assignments whatsoever could be made for residues 18, 34 -37, 50, 63, 68, and 69 in that study. For the studies performed with acetic acid present (6, 8) , virtually complete assignments were accomplished.
Once our attempts were started to form complexes between IGF-I and IGFBP-1, it became clear that spectral quality for the complex was improved by lowering the temperature to 30°C. For internal consistency, the backbone assignment procedure was repeated on a fresh sample of 13 C, 15 N-IGF-I, but now at 30°C and pH 3.4. The spectral quality of IGF-I alone at this temperature, however, only allows partial assignments. The IGF-I residues for which any assignments can be made unambiguously at 30°C ␦ and 13 C ␥ chemical shifts are very similar and only vary by a few tenths of a ppm, respectively. To match these with the correct residue, it is necessary to assign the 13 C ␦ and 13 C ␥ chemical shifts, for instance, in a CC(CO)NH-total correlation spectroscopy experiment. The spectral quality of this experiment is too poor (particularly for free IGF-I at 30°C) to unambiguously assign the IGF-I arginine 13 
C
␦ and 13 C ␥ nuclei. Consequently, it has not been possible, in our hands, to uniquely assign the arginine guanidino groups of IGF-I, and subsequently deconvolute the arginine participation in the IG-FBP-1 binding epitope, using current NMR techniques alone.
Instead, arginine to alanine substituted IGF-I variants R21A, R36A/R37A, R50A, R55A, and R56A were constructed by site-specific in vitro mutagenesis. Clones were DNA-sequenced and found to correspond to the anticipated sequences. The IGF-I and IGF-I variants were produced in E. coli and purified to homogeneity, essentially as described previously for other IGF-I variants (20) . Quantitative analysis of amino acid composition and determined molecular masses correspond to the theoretically expected values for all variants (data not shown).
The far-UV CD spectra of IGF-I and the IGF-I variants were determined (Fig. 3) . The spectra are almost completely coinciding over the entire wavelength range, indicative of a highly similar overall secondary structure content. Because of this lack of structural changes, all variations in binding affinities between IGF-I and its variants are expected to be caused by differences in side chain properties.
The kinetic measurements of IGF-Is binding to IGFBP-1 and IGF-I R (Fig. 4) were performed at a number of different concentrations for each ligand. The total estimated error from concentration determination, pipetting, and data fitting was less than 10%, corresponding to a calculated error of less than 10% in the measured rates and less than 22% in the calculated K a values. The results from the biosensor measurements of IGF-I arginine-substituted variants are summarized in Table  II . In the binding of IGF-I variants to IGFBP-1, R36A/R37A, R50A, and R55A display significantly altered association rates (k a ), whereas only R36A/R37A and R50A have significantly changed dissociation rates (k d ). The binding kinetics of arginine-substituted variants to IGF-I R display alterations in both association and dissociation. The R21A, R36A/R37A, and R50A have decreased association rates. Dissociation is significantly increased for the R21A, R36A/R37A, and R56A variants.
The binding of IGF-I to immobilized IGF-I R was studied in the presence of different ratios of IGFBP-1, to test for the presence of overlapping IGFBP-1 and IGF-I R binding epitopes. 
TABLE II BIAcore kinetics for IGF-I variants binding to IGFBP-1 and IGF-I R .
The calculated total error of 10% in rate determinations, corresponding to a total of 22% error in calculated affinity is indicated in the 
IGFBP-1 Binding Epitope on IGF-I
The IGF-I⅐IGFBP-1 complex does not bind to the receptor when the IGFBP-1 excess is 5-fold as shown in Fig 99 residues) were observed, while the larger interaction partner CD48 (soluble part; 193 residues) was successively added. The study presented here, where a 23-kDa protein is docked to a 7-kDa target, had to be conducted on a preformed complex. Previous observation of the aggregation tendencies of IGFBP-1, as well as IGF-I, when free in solution, necessitated the formation of the complex at dilute conditions with an excess of IG-FBP-1 and subsequently concentrated.
The chemical shift differences found in IGF-I when comparing the molecule alone and in complex with IGFBP-1 involve residues (Table I and Fig. 6 ). This area spans the better part of one face of the molecular surface. For comparison, the amino acid residues so far identified to affect IGFBP-1 affinity in mutagenesis studies are also shown in Fig. 6 . The mutations known to affect IGFBP-1 affinity are found highly localized in a small portion of, but not constrained to, the interaction surface as defined by NMR. The arginine residues (positions 21, 36, 37, 50, 55, and 56) all circle the area where the chemical shift perturbations are found. It is, however, geometrically consistent that IG-FBP-1 affinities are unaffected by mutating residues 21, 55, and 56, since they are most distant from the interaction surface. One interesting observation is that the chemical shifts of the C-terminal residues, Lys 68 -Ala 70 , are perturbed by the presence of IGFBP-1. In this study, two alternative conformations of the C-terminal IGF-I polypeptide segment Ala 67 -Ala 70 can be observed for free IGF-I at 30°C but not 50°C. The 15 (Table I) . It is conceivable that the chemical shift perturbations observed for the C terminus of IGF-I (light green in Fig. 6 ) upon the addition of IGFBP-1 at 30°C, are a result of a change in its conformational equilibrium to favor the (in free IGF-I) less populated conformation. As a consequence of this, chemical shift differences might be observable between the free and complexed form of IGF-I that result from a different conformational population, i.e. indirect structural changes, and not direct contact with the binding protein.
In light of this observation, it is possible that none of the residues in the C terminus (Pro 63 -Ala 70 ) participate in making structural contact with IGFBP-1. This is in accordance with the binding studies performed on the fusion protein IGF-I-Z, where the IgG binding staphylococcal protein A module Z was fused directly to the C terminus of IGF-I (43). The IGFBP-1 binding on-rate to IGF-I-Z was found to be reduced to 23% of the wild-type value, while the off-rate remained essentially the same. The unchanged dissociation rate would indicate that the C terminus is not directly involved in the functional epitope. Bulky extensions such as Z would, on the other hand, cause steric hindrance for IGFBP-1 to approach IGF-I-Z as judged by the lowered association rate. The 15 N and 13 C ␣ shifts of Gly 7 both change by more than 1 ppm (when temperature effects have been accounted for) when the temperature is lowered from 50 to 30°C. The 15 N chemical shift for Ser 51 is also perturbed more than expected by just temperature differences. This observation and the fact that the disulfide-connected residues Cys 6 and Cys 48 could not be assigned in free IGF-I at any temperature raise the question of whether this disulfide bond is undergoing intermediate exchange. Otting et al. (44) have described how a minor form of bovine pancreatic trypsin inhibitor was found to correspond to the cis isomer of a disulfide bond and has shown that this conformational equilibrium leads to attenuation of signals from residues in the vicinity of this bond. It is tempting to suggest that part of the problem with the spectral quality of IGF-I, especially at ambient temperatures, stems from such a conformational exchange between cis and trans disulfide bonds between Cys 6 and Cys 48 (cf. Fig. 1 ). Supporting such a speculation is the fact that cross-peaks from the 13 C ␣ and 13 C ␤ nuclei of Cys 6 can be observed after IGFBP-1 has been added to the IGF-I molecule, suggesting that the kinetics of this exchange is affected by the presence of IGFBP-1. It is possible that the two observed C-terminal conformations correspond to the cis and trans isoforms of the Cys 6 -Cys 48 disulfide bond. The Ser 51 residue packs next to the C-terminal residue Ala 70 (Fig. 6) , and a conformational change in the area of the disulfide bond could be translated to the C terminus. IGF-I is a notoriously difficult molecule to study structurally. Over a decade of attempts have not yielded any crystal structures, and the NMR structures (5, 8, 9) are fraught with problems. The cis-trans isomerization hypothesis has yet to be proven but aids in advancing the understanding of the dynamic nature of the IGF-I molecules structure, which could be a possible explanation, apart from the aggregation tendencies of IGF-I, for this elusiveness.
Detailed studies of the intermolecular interactions between human growth hormone and the soluble form of its receptor (hGHbp) have shown that the functional binding epitope, contributing to the actual binding energy, can be significantly smaller than the structural binding epitope, as defined by x-ray crystallography (17) . While human growth hormone involves 33 side chains in the interaction with hGHbp, two of these contribute 75% of the total binding energy. In this regard, it is interesting to probe the importance of single residues within the structural IGFBP-1 binding epitope on IGF-I defined by the NMR experiments. Arginine side chain guanidino groups are found to be central in stabilizing interactions between proteins (45), between proteins and drugs (46) , and between proteins and DNA (47), and they therefore constitute logical targets for such probing. Given the observed involvement of IGF-I arginine side chains in IGFBP-1 binding by NMR spectroscopy, we have concentrated our initial probing, presented in this report, to the six arginine residues surrounding the identified structural binding epitope.
The CD secondary structure analysis shows that the arginine to alanine mutants have similar secondary structure content as native IGF-I and are likely to share the same overall fold. This contrasts with our previous study on IGF-I alanine scanning mutants of the IGF-I B-helix region (19) (residues 8 -18), where structural aberrations occurred in single substituted variants, resulting in altered kinetic properties due to the change in structure. The present mutants are all at charged surface residues, positions apparently less influential on the overall structure. The measured changes in binding characteristics are thus likely to be only the result of side chain properties and not contributions from global structural rearrangements in the molecule.
One arginine residue, Arg 50 , is unambiguously determined by biosensor technology to be involved in IGFBP-1 binding, since the R50A mutant has about a third of the wild type affinity. The R36A/R37A double mutant affinity is also lowered, but the individual amino acid contributions cannot be distinguished. The observed decreased association and minor influence on dissociation for these mutants is consistent with neutralizing charged residues that contribute to binding electrostatically during association but do not contribute significantly to the stability of the formed complex.
From these results and from data in the literature, we can make a model of the patch on IGF-I involved in IGFBP-1 binding (Fig. 6) . The surface expands from the small surface patch of previously identified amino acids 1-4 (15, 16) and 49 -51 (16) with one arm into the area of residues 36/37. The 36/37 region is known also to be important for IGF-I R binding. Therefore, these measurements would explain why IGFBP-1 and IGF-I R binding is competitive. The effects of the arginine mutants on receptor binding shows that the affinities are affected to a greater extent than in IGFBP-1 binding. The association rate decreases in all cases, although significantly only for R21A, R50A, and especially the C-region R36A/R37A double mutant. The importance of the C-region (residues 30 -41) in IGF-I R binding has been stated previously (48) . The increased dissociation rates for the R21A, R36A/R37A, and R56A variants show the direct involvement of these residues in IGF-I⅐IGF-I R complex stabilization. The IGF-I⅐IGFBP-1 complex does not associate to immobilized IGF-I receptor (Fig. 5) . This observation leads to the conclusion that only free IGF-I is capable of binding to the IGF-I R , since the binding determinants on IGF-I for IGFBP-1 and IGF-I R are overlapping. It is consequently likely that the reverse experiment, attempting to accelerate IGF-I disassociation from IGF-I R by the presence of IGFBP-1, would show no difference because of the overlapping IGF-I R and IGFBP-1 binding epitopes on IGF-I. The finding that the receptor undergoes a conformational change upon ligand binding (20) , possibly hiding the ligand further, supports this conclusion.
The IGF-I arginines are highly conserved in vertebrates. The only common variant is the arginine to glutamine substitution at position 50 in chicken, frog, and salmon. The arginine at position 55 is interesting in that it actually has a slower IG-FBP-1 association compared with the R55A mutant. We conclude that arginine 55 is not directly involved in stabilizing IGF-I R binding, and the conservation of this residue therefore suggests that it is important for other functions (e.g. specificity in binding to other ligands, such as other IGFBPs or receptors). It has previously been demonstrated that replacement of the homologous residues in IGF-II, Ala-Leu, to the IGF-I sequence 
